Drug Discovery & Development

Drug Discovery & Development magazine provides valuable insights into the entire spectrum of technologies, tools, and business and regulatory approaches that assist scientists and business leaders in speeding up the process and efficiency of drug research and development. The articles are brief and focused, aimed at delivering useful information for everyday technical and business choices.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#776434

United States

#421060

Health/Biotechnology and Pharmaceuticals

#390

Traffic sources

Monthly visitors

Articles

Trump slams 'global free ride' on drug pricing in MFN executive order

4 days ago | drugdiscoverytrends.com | Brian Buntz

Branding U.S. drug pricing an “egregious imbalance” in which a nation with “less than five percent of the world’s population … funds around three‑quarters of global pharmaceutical profits,” President Donald Trump on 12 May signed the Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients order.
Intrepid Labs raises $7 million to boost AI-driven formulation platform

4 days ago | drugdiscoverytrends.com | Brian Buntz

Toronto-based Intrepid Labs, which we profiled a year ago, has closed an Avant Bio-backed $7 million seed round, bringing its total financing to over $11 million. The company’s Valiant platform is an autonomous lab technology that pairs machine-learning algorithms with robotics to potentially explore up to 1 billion possible formulations. It aims to cut drug-product design from months to days.
FDA's genAI push could save CDER hundreds of thousands of review hours annually

1 week ago | drugdiscoverytrends.com | Brian Buntz

Determined to slash bureaucratic drag on drug approvals, FDA chief Dr. Martin Makary is ordering every center to plug generative-AI tools into its review pipeline by June 30, an agency-wide gamble that, he says, will turn days of paperwork into minutes of analysis.
AI agents could shoulder 55% of biopharma work, Accenture study finds

1 week ago | drugdiscoverytrends.com | Brian Buntz

Are AI agents more substance or hype in biopharma? A new report from Accenture and Wharton suggests they are the real deal in biopharma. The two organizations found AI agents, essentially software and physical bots working with minimal oversight, can impact approximately 55% of total workforce hours within a typical biopharma firm.
Elsevier adds 500,000 ClinicalTrials.gov records into Embase

1 week ago | drugdiscoverytrends.com | Brian Buntz

Elsevier has pushed roughly half a million ClinicalTrials.gov entries into Embase, its subscription biomedical database. The May 6 update lets R&D teams run a single search that pulls trial data from 200‑plus countries and matches it with Embase’s peer‑reviewed papers, in‑press manuscripts and conference abstracts. Elsevier notes that traditional approaches to synthesizing data from multiple sources is error prone and tedious.
Can space help heal hearts? ISS study charts new path for stem cell therapy

1 week ago | drugdiscoverytrends.com | Brian Buntz

Emory University stem-cell biologist Chunhui Xu is looking to space for a new way to mend damaged hearts on Earth. Her team is using the International Space Station (ISS) National Lab to test if the near-weightless environment of microgravity can make heart cells divide faster and survive longer, a novel approach borrowed from cancer researchers who noticed tumors grow more aggressively in orbit. The research aims to overcome a fundamental challenge: once cardiac muscle dies, it barely regrows.
Deloitte explores what's fueling Big Pharma's R&D IRR climb

2 weeks ago | drugdiscoverytrends.com | Brian Buntz

Pharma’s long winter of diminishing R&D returns may be thawing. Despite decades of increased spending yielding less bang for the buck, the industry is regaining ground. Deloitte’s closely watched annual analysis charted the slide, with average forecast IRR falling from just over 10% in Deloitte’s inaugural 2010 analysis to a trough of just 1.5% by 2019, a period that “almost was a linear decline,” according to Kevin Dondarski, Principal for US Life Sciences Strategy at Deloitte Consulting LLP.
Jane Li on aligning drug-test launches

2 weeks ago | drugdiscoverytrends.com | Brian Buntz

Precision medicine promises the “right drug, right patient” mantra. One piece that sometimes goes missing? A test approved on day one. Jane Li has spent two decades making sure that gap closes on schedule.
Inside CheckImmune’s playbook for cell-specific drug insights

2 weeks ago | drugdiscoverytrends.com | Brian Buntz

At next week’s National Biotechnology Conference, Berlin-based clinical research firm CheckImmune GmbH will showcase how layering single-cell multi-omics provides insights into drug action and immune responses that bulk readouts (averaged measurements from a large population of cells) often miss.
MIT team designs gene circuits for precise control in gene therapy study

2 weeks ago | drugdiscoverytrends.com | Brian Buntz

An MIT research group has unveiled a set of synthetic gene circuits designed to give scientists more control over gene-therapy treatments, according to a recent paper. The study, appearing in the journal Cell Systems, describes genetic constructs meant to fine-tune how and when therapeutic genes are switched on inside a patient’s cells, aiming to keep expression levels within a specific target range and potentially aiding treatments for diseases like Fragile X syndrome.